Factors such as strict price controls, reduced government investment in basic research, weak collaboration between industry and universities, and a slow regulatory process have significantly contributed to the decline in Japan's biopharmaceutical competitiveness, as noted in a 2022 paper by the Centre for Life Sciences Innovation, part of the Information Technology and Innovation Foundation, US. Japanese companies’ share of clinical trials also declined from 11 per cent in 2013 to 4 per cent in 2023. An IQVIA report found that the number of trials initiated by Japanese companies dropped from 501 in 2013 to 244 a decade later. Additionally, Japan launched only 20 new medicines in 2023, the lowest total since 2014, trailing behind the US and other major markets. Recognising this, the Japanese government has announced several initiatives designed to reshape the country’s biopharma ecosystem. These efforts include substantial increases in capital for venture funds, targeted subsidies for therapeutic drug development, and a suite of tax incentives aimed at empowering investors, entrepreneurs, and startup employees.
On July 30 2024, Japanese Prime Minister Fumio Kishida unveiled a roadmap to establish Japan as a ‘drug discovery land,’ marking it as a top government priority. The plan includes creating international-level clinical trial systems, attracting global pharmaceutical companies and venture capital, and doubling private investments in drug discovery startups by 2028. The aim is to foster an environment that supports both academia and startups, accelerates innovation, and enhances Japan’s role in the global pharmaceutical industry.
هذه القصة مأخوذة من طبعة BioSpectrum Asia Sep 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة BioSpectrum Asia Sep 2024 من BioSpectrum Asia.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.